<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01860911</url>
  </required_header>
  <id_info>
    <org_study_id>12-005173</org_study_id>
    <nct_id>NCT01860911</nct_id>
  </id_info>
  <brief_title>Plasma Triglyceride Extraction by The Muscle</brief_title>
  <official_title>Regulation of the Plasma Triglyceride Extraction in Muscle in Insulin Resistance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Diabetes Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Increased accumulation of fat into the muscles is associated with what is called
      insulin-resistant state, which is a pre-diabetic state. The purpose of this research is to
      find out how fat circulating in the blood following fat consumption is taken up by the
      muscles in healthy people as well as people that are insulin-resistant. The investigators are
      specifically interested in how a hormone called insulin is involved in this process. Findings
      from this research will contribute to our understanding of why insulin-resistant people have
      increased accumulation of fat in their muscles, and ultimately help to design appropriate
      interventions to prevent type 2 Diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Triglyceride extraction across the forearm</measure>
    <time_frame>Measured during a 7-hour infusion study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Muscle microvascular blood volume</measure>
    <time_frame>Selected 15-minute periods during the 7 hour infusion study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Obesity</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Insulin-Sensitive</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One group consists of insulin sensitive volunteers.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin-Resistant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One group consists of insulin resistant volunteers.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin</intervention_name>
    <arm_group_label>Insulin-Sensitive</arm_group_label>
    <arm_group_label>Insulin-Resistant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NG-monomethyl-L-arginine</intervention_name>
    <arm_group_label>Insulin-Sensitive</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index (BMI): &lt; 25 kg/m2 or &gt; 30 kg/m2;

          -  Insulin sensitivity index (ISI): insulin-sensitive ISI ≥ 7, insulin-resistant ISI ≤ 5.

        Exclusion Criteria:

          -  Medication or supplements known to affect either endothelial function or lipid
             metabolism (i.e. arginine, protein, fish oil)

          -  Acute illness

          -  Uncontrolled metabolic disease, including liver or renal disease

          -  Atrial fibrillation, history of syncope, limiting or unstable angina, congestive heart
             failure, known or suspected right-to-left, bi-directional or transient right-to-left
             cardiac shunts

          -  Cardiac pacemaker or other medical device implanted in the body

          -  Pulmonary hypertension or other unstable cardiopulmonary conditions

          -  ECG documented abnormalities or valvular disease

          -  Low hemoglobin or hematocrit (i.e., lower than accepted laboratory values)

          -  History of hypertension or elevated blood pressure (systolic, &gt;140 mmHg or a
             diastolic, &gt;95 mmHg)

          -  History of hyperlipidemia or plasma triglyceride concentration &gt;200 mg/dl

          -  Diagnosed diabetes, or 2-h plasma glucose &gt;200 mg/dl during an oral glucose tolerance
             test

          -  Current participation in a weight-loss regimen, including extreme dietary practices

          -  Use of anabolic steroids or corticosteroids (within 3 months)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lori Roust, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christos S Katsanos, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Arizona State University/Mayo Clinic Arizona</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Charlene Robinson</last_name>
    <phone>480-301-4626</phone>
    <email>ARZClinicalStudies@mayo.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic in Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlene Robinson</last_name>
      <phone>480-301-4626</phone>
      <email>ARZClinicalStudies@mayo.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2013</study_first_submitted>
  <study_first_submitted_qc>May 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2013</study_first_posted>
  <last_update_submitted>November 22, 2017</last_update_submitted>
  <last_update_submitted_qc>November 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Lori R. Roust</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>omega-N-Methylarginine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

